Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-060299
Filing Date
2025-04-29
Accepted
2025-04-29 17:00:24
Documents
19
Period of Report
2025-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A eldn-20250429.htm   iXBRL DEF 14A 1075096
2 GRAPHIC img118025896_0.jpg GRAPHIC 191772
3 GRAPHIC img118025896_1.jpg GRAPHIC 959267
4 GRAPHIC img118025896_2.jpg GRAPHIC 935638
5 GRAPHIC img118025896_3.jpg GRAPHIC 1388381
6 GRAPHIC img118025896_4.jpg GRAPHIC 147454
  Complete submission text file 0000950170-25-060299.txt   10594200

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eldn-20250429.xsd EX-101.SCH 12025
22 EXTRACTED XBRL INSTANCE DOCUMENT eldn-20250429_htm.xml XML 393409
Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36620 | Film No.: 25888950
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)